Welcome to our dedicated page for Aspira Women`s Health news (Ticker: AWH), a resource for investors and traders seeking the latest updates and insights on Aspira Women`s Health stock.
Aspira Women's Health Inc. (AWH) delivers innovative diagnostic solutions for gynecologic diseases through its AI-powered blood tests. This comprehensive news hub provides investors and healthcare professionals with essential updates on the company's advancements in ovarian cancer risk assessment and women's health diagnostics.
Access timely reports on regulatory milestones, clinical study results, and financial performance. Our curated collection includes press releases about OvaWatch developments, partnership announcements with medical institutions, and analyses of emerging trends in precision diagnostics.
Key content categories cover earnings reports, product innovation updates, strategic collaborations, and peer-reviewed research validations. Each update maintains clinical context while focusing on business implications for informed decision-making.
Bookmark this page for centralized access to Aspira's evolving diagnostic portfolio and market-moving announcements. Check regularly for objective reporting on developments impacting women's healthcare and diagnostic technology sectors.
Aspira Women's Health (Nasdaq: AWH) announced a $1.935 million private placement equity financing. The agreement, dated June 30, 2024, involves issuing 1,264,739 shares of common stock and warrants to purchase an equal number of shares at $1.53 per share. The warrants have a three-year term and an exercise price of $2.25 per share. The financing is expected to conclude by July 8, 2024, with proceeds supporting ongoing commercial activities and general corporate purposes. CEO Nicole Sandford highlighted the strong shareholder support and focus on commercial growth, following the expansion of the OvaSuite test portfolio and recent clinical data. The issued securities are unregistered and will be registered for resale with the SEC.
Aspira Women’s Health (Nasdaq: AWH) reported significant commercial and operational updates for Q2 2024. Key highlights include a monthly product volume increase of over 26% from January to May 2024, and a year-to-year growth in sales representative productivity. OvaWatch volume surged by 88%, and the company is expanding to the Philippines with higher margin expectations. Reimbursement has progressed with new Anthem and Medicaid coverage, potentially adding 16 million lives in upcoming quarters. Anticipated guidance shows a reduction in cash used in operations for 2024.
Aspira Women’s Health (Nasdaq: AWH), a company specializing in gynecologic disease diagnostics, will present at the A.G.P. Healthcare Showcase on May 21, 2024. The corporate overview will be delivered virtually at 11:00 am EST. Management will also be available for one-on-one meetings with registered investors.
Aspira Women’s Health (Nasdaq: AWH) reported its Q1 2024 financial results. Key highlights include $2.2 million in OvaSuiteSM revenue and 5,829 units sold, with a 22% decrease in cash utilization compared to Q1 2023. Notably, OvaWatch volume grew 114% year-over-year, and gross margin reached 56% from 51% in the prior year. Aspira also saw significant decreases in R&D, sales and marketing, and general administrative expenses. The company ended the quarter with $3.7 million in cash, up from $2.9 million at the end of 2023, and raised $5.6 million through a direct offering. Key corporate developments include a study validating OvaWatch for ovarian cancer management, a new reimbursement agreement with Anthem Blue Cross, and the launch of OvaWatch’s longitudinal monitoring feature.
Aspira Women’s Health Inc. will announce its first-quarter earnings results for the period ending March 31, 2024, on May 15, 2024. The company, focused on developing gynecologic disease diagnostic tools, will also host a conference call on the same day to discuss financial results and provide a corporate update.
Aspira Women’s Health Inc. announced the publication of two peer-reviewed manuscripts related to OvaWatch, a tool for ovarian cancer risk assessment. The studies showed that OvaWatch can help in stratifying risk in patients with adnexal masses and monitoring ovarian cancer risk in women with low risk masses. The company aims to accelerate the adoption of OvaWatch as an alternative to surgical intervention for lower risk cases.
Aspira Women’s Health Inc. announced the formal launch of the updated OvaWatch ovarian cancer risk assessment test, utilizing an AI-powered algorithm to assess malignancy risk of adnexal masses. OvaWatch offers a negative predictive value of 99%, aiding physicians in determining the appropriate care plan over time. The longitudinal monitoring feature enhances the OvaWatch offering, providing a powerful tool for assessing malignancy risk in women with adnexal masses without the need for unnecessary surgery.
FAQ
What is the current stock price of Aspira Women`s Health (AWH)?
What is the market cap of Aspira Women`s Health (AWH)?
